The stock of Heska Corp (NASDAQ:HSKA) hit a new 52-week high and has $155.97 target or 176.00% above today’s $56.51 share price. The 7 months bullish chart indicates low risk for the $452.42M company. The 1-year high was reported on Nov, 2 by Barchart.com. If the $155.97 price target is reached, the company will be worth $796.26 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 38,473 shares traded hands. Heska Corp (NASDAQ:HSKA) has risen 101.86% since March 31, 2016 and is uptrending. It has outperformed by 99.34% the S&P500.
Analysts await Heska Corp (NASDAQ:HSKA) to report earnings on November, 9. They expect $0.26 earnings per share, up 30.00% or $0.06 from last year’s $0.2 per share. HSKA’s profit will be $2.08 million for 54.34 P/E if the $0.26 EPS becomes a reality. After $0.35 actual earnings per share reported by Heska Corp for the previous quarter, Wall Street now forecasts -25.71% negative EPS growth.
Heska Corp (NASDAQ:HSKA) Ratings Coverage
Out of 2 analysts covering Heska Corp (NASDAQ:HSKA), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Heska Corp has been the topic of 3 analyst reports since August 25, 2015 according to StockzIntelligence Inc. The stock has “Neutral” rating given by CL King on Friday, April 1. The stock of Heska Corp (NASDAQ:HSKA) earned “Hold” rating by Gabelli on Thursday, August 4. The company was upgraded on Tuesday, August 25 by TheStreet.
According to Zacks Investment Research, “Heska Corporation is focused on the discovery, development and marketing of companion animal health products. In addition to manufacturing certain of companion animal products, the company’s primary manufacturing subsidiary, Diamond Animal Health, Inc., also manufactures animal health vaccine products which are marketed and distributed by third parties. In addition to manufacturing veterinary allergy products for marketing and sale by the company, subsidiaries, Center Laboratories, Inc. and CMG-Heska Allergy Products S.A., also manufacture and sell human allergy products.”
Insitutional Activity: The institutional sentiment increased to 1.54 in Q2 2016. Its up 0.10, from 1.44 in 2016Q1. The ratio is positive, as 6 funds sold all Heska Corp shares owned while 29 reduced positions. 24 funds bought stakes while 30 increased positions. They now own 4.56 million shares or 4.63% more from 4.36 million shares in 2016Q1.
Wells Fargo And Mn holds 0% or 2,828 shares in its portfolio. Goldman Sachs Grp last reported 13,307 shares in the company. Manufacturers Life Insurance The accumulated 4,711 shares or 0% of the stock. Hatteras Funds Ltd holds 2.29% of its portfolio in Heska Corp (NASDAQ:HSKA) for 11,010 shares. Rhumbline Advisers last reported 5,966 shares in the company. The United Kingdom-based Gsa Prtnrs Llp has invested 0.17% in Heska Corp (NASDAQ:HSKA). The Massachusetts-based State Street has invested 0% in Heska Corp (NASDAQ:HSKA). Moreover, Walleye Trading Ltd has 0% invested in Heska Corp (NASDAQ:HSKA) for 400 shares. Numeric Invsts Ltd holds 14,336 shares or 0% of its portfolio. Teachers Advsr Inc, a New York-based fund reported 9,129 shares. Fuller Thaler Asset Management holds 1,500 shares or 0% of its portfolio. Fred Alger Management Incorporated holds 0.01% or 58,646 shares in its portfolio. Commercial Bank Of New York Mellon last reported 0% of its portfolio in the stock. Millennium Mgmt Ltd holds 0.01% of its portfolio in Heska Corp (NASDAQ:HSKA) for 105,069 shares. California Public Employees Retirement Sys last reported 0% of its portfolio in the stock.
Insider Transactions: Since May 3, 2016, the stock had 0 insider purchases, and 14 sales for $5.86 million net activity. 5,000 shares with value of $178,750 were sold by NAPOLITANO JASON A on Tuesday, May 3. McGinley Michael J also sold $218,927 worth of Heska Corp (NASDAQ:HSKA) on Tuesday, May 10. McMahon John sold $7,028 worth of Heska Corp (NASDAQ:HSKA) on Wednesday, August 24. Another trade for 20 shares valued at $879 was sold by Wilson Kevin S.. $246,864 worth of shares were sold by Asakowicz Steve on Tuesday, August 9. Riley Sharon L. had sold 15,000 shares worth $534,863 on Thursday, May 5.
Another recent and important Heska Corp (NASDAQ:HSKA) news was published by Marketwatch.com which published an article titled: “Heska downgraded to neutral from buy at B. Riley” on December 21, 2009.
HSKA Company Profile
Heska Corporation, incorporated on March 27, 1997, develops, makes, markets, sells and supports veterinary products. The Firm is focused on the canine and feline companion animal health markets. The Firm operates in two divisions, which include Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use services and products, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing. The OVP segment includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals. It sells veterinary diagnostic and other specialty veterinary products. The Company’s offerings include blood testing instruments and supplies, digital imaging products, software and services, and single use services and products, such as in-clinic heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.